Trial-anchored psychedelic practice guidance

KAP treatment model knowledge

Understands ketamine-assisted psychotherapy as an enhancement to psychotherapy involving ketamine dosing sessions followed by integration therapy. Can explain the intended therapeutic process, typical course of treatment, and the role of dissociation/psychedelic experience in growth and change.

Informed consent facilitation

Ensures the patient understands the nature, benefits, risks, alternatives, and limits of ketamine-assisted psychotherapy before treatment begins. Supports voluntary, well-informed participation and respects the right to withdraw before administration.

In-session monitoring and observation

Continuously monitors the patient during ketamine administration for physiological and psychological safety. Recognizes that a medical practitioner must be present on the premises at all times.

Manualized existential psychotherapy delivery

Facilitators must deliver Meaning and Purpose (MaP) therapy as a manualized existential behavioral intervention. The work is structured around helping participants reflect on illness, life meaning, values, relationships, and sources of fulfillment.

Safety monitoring during ketamine administration

Facilitators and study clinicians must continuously monitor for acute physiologic and psychiatric effects during ketamine dosing. They must recognize and respond to changes in blood pressure, heart rate, oxygenation, anxiety, psychosis, and dissociation.

Medical emergency recognition and response

Study personnel must recognize medical instability and respond promptly to potentially serious ketamine-related events. The on-site physician must be prepared to evaluate cardiovascular complications and coordinate escalation of care.

Study record management knowledge

The facilitator should understand study record management concepts relevant to clinical trial registration and results reporting. This includes awareness of how study data are defined and submitted in official trial records.

Registry-based documentation awareness

Ability to work within the constraints of registry-based information and understand what can and cannot be inferred from the source. This supports accurate extraction without overinterpreting sparse text.

Compliance with registration standards

Responsibility to follow ClinicalTrials.gov registration and results submission standards when interacting with study records. This includes using the appropriate data element definitions for accurate reporting.

Clinical trial record interpretation

Ability to understand and interpret ClinicalTrials.gov study records and associated metadata. This includes recognizing that the source is a study registry entry and that content may be limited to administrative or protocol-level information.

Ketamine-assisted psychotherapy delivery

Able to deliver ketamine-assisted psychotherapy for patients with chronic pain and comorbid major depressive disorder. Understands that treatment may be delivered using different dosing/administration paradigms.

Symptom monitoring and outcome tracking

Monitors depression, pain, anxiety, PTSD symptoms, and subjective psychedelic experience over the course of treatment. Uses repeated measurement to assess clinical change and treatment response.

Ethical use of preliminary evidence

Recognizes the limits of pilot and observational evidence and avoids overclaiming efficacy. Communicates findings responsibly in light of small sample size and preliminary design.

Study record management

Understand how to use the ClinicalTrials.gov study record framework and related definitions when submitting or reviewing registration information. This includes knowing where to locate official data element definitions and glossary terms.

Ketamine psychotherapy delivery

Deliver ketamine-assisted psychotherapy in a structured preparatory, dosing, and integration format. The therapist supports an initial non-directive experiential phase followed by directed processing and integration of session material.

Suicide risk assessment and monitoring

Identify and monitor suicidal ideation and other acute safety concerns before, during, and after treatment. The protocol requires structured C-SSRS use and immediate post-session safety checks.

Informed consent process

Ensure valid informed consent before any study procedures begin. The process requires clear explanation of risks, benefits, and study expectations, with signed documentation by the participant or legally authorized representative.

Suicide and serious psychiatric risk assessment

Competence to identify participants at elevated suicide risk and respond with exclusion, urgent referral, or withdrawal from the study. Safety monitoring is emphasized before and throughout treatment.

Physiologic monitoring during ketamine administration

Skill in tracking vital signs and recognizing medically significant changes related to ketamine. The protocol requires monitoring blood pressure, pulse, respiration, temperature, and oxygenation before and after dosing.

Informed consent, decisional capacity, autonomy, and withdrawal rights

Competence to obtain ethically valid informed consent by ensuring comprehension, voluntariness, and adequate opportunity for discussion. Only qualified study physicians or co-investigators may obtain consent in this protocol.

Study record and trial registration literacy

Therapist/facilitator should understand the study record and its required elements well enough to support accurate registration and reporting. This includes familiarity with ClinicalTrials.gov terminology and data element definitions.

Informed consent process

Ability to explain the study clearly and obtain voluntary written informed consent before any study procedures. Consent must be completed in a way that supports participant understanding and autonomy.

Ketamine infusion monitoring

Ability to monitor participants during subanesthetic ketamine or active placebo infusion and respond to acute changes. This is a core applied clinical competency in the protocol.

Suicide and serious psychiatric risk assessment

Ability to assess imminent risk and escalate care when safety concerns emerge. The protocol requires termination and urgent evaluation if active suicidal or homicidal planning develops.

Informed consent, decisional capacity, autonomy, and withdrawal rights

The therapist/facilitator must ensure participants understand the study and voluntarily consent before any study procedures occur. Consent must be obtained in accordance with regulatory requirements and local IRB rules.

Depression symptom monitoring

The facilitator must monitor depressive symptoms closely across treatment and follow-up using standardized scales and clinical review. Response classification depends on these measurements.

Suicide risk assessment and monitoring

The facilitator must actively assess suicidality at each visit and respond to worsening risk immediately. Suicide-related events are specifically monitored as adverse events and serious adverse events.

Knowledge of PTSD treatment hierarchy and rationale for PE

Therapists should know that the cited VA/DoD guideline recommends individual manualized trauma-focused therapy such as PE over pharmacologic interventions as primary PTSD treatment. This knowledge supports appropriate framing of the adjunctive role of ketamine.

Deliver manualized trauma-focused prolonged exposure therapy

Therapists should be able to provide individual, manualized Prolonged Exposure (PE) therapy as the core PTSD treatment approach in this protocol. Competence includes adhering to the structured PE sequence across the full treatment course.

Coordinate adjunctive ketamine or active placebo with psychotherapy timing

Facilitators and treating clinicians must understand and operationalize the study-specific timing between infusions and exposure sessions. This includes aligning infusion administration 24 hours before PE sessions during the first 3 weeks.

Informed consent, decisional capacity, autonomy, and withdrawal rights

Ability to ensure participation is voluntary and informed. The facilitator must confirm the participant understands the study and freely agrees without coercion.

TRD eligibility assessment

Ability to determine whether a participant meets treatment-resistant depression criteria for ketamine treatment studies. This includes understanding diagnostic and treatment-failure thresholds used for enrollment.

Physiologic monitoring during ketamine administration

Ability to monitor vital signs and physiologic stability during ketamine treatment. This is essential for detecting acute adverse reactions or instability.

Ketamine-assisted psychotherapy adaptation

Therapists must adapt standard CBT to the ketamine-assisted context using a specific therapist manual. This includes set-and-setting work, intention-setting, grounding, and integrating ketamine experiences into subsequent CBT sessions.

Manualised CBT delivery for methamphetamine use disorder

A core facilitator skill is delivering the four-session manual-based cognitive behavioural therapy intervention tailored to methamphetamine use disorder. The therapist must follow the structured programme while addressing substance use history, mental health, readiness to change, and between-session practice.

Integration-focused post-dose psychotherapy

Therapists must be able to conduct post-ketamine integration in a focused, clinically useful way. This involves exploring the participant’s subjective ketamine experience briefly and linking it to CBT targets and recovery goals.

Preparation for altered-state experience

A major therapist competency is preparing patients extensively for the ketamine session, including the nature of the special state of consciousness and possible ego dissolution or separation from the body. Preparation is both educational and psychotherapeutic.

Post-session integration psychotherapy

A core competency is helping patients interpret and integrate ketamine-session experiences into everyday life and recovery. Integration occurs immediately after sessions and includes linking symbolic content to addiction-related problems.

Safety monitoring during ketamine sessions

Ketamine sessions require active medical safety monitoring because complications, though rare, are possible. The therapist must work in a medically supervised environment with continuous anesthesiology presence.

Trauma-informed group ketamine-assisted therapy delivery

Facilitators need competence in delivering group-based ketamine-assisted therapy within a trauma-aware, resilience-focused clinical protocol. This includes using structured weekly group processes and embedding ketamine sessions within a broader therapeutic program rather than treating medication as the sole intervention.

Relational accountability and cultural humility

The protocol emphasizes ethical responsibilities grounded in relational accountability and cultural humility. Facilitators should approach participants, communities, and knowledge systems with respect, self-awareness, and accountability.

Group facilitation and relational process leadership

Therapists and facilitators must be able to guide intentional group process in a way that supports safety, connection, and meaningful change. This includes managing both large- and small-group formats and maintaining a relationally anchored therapeutic environment.

Independent blinded rating

Performs clinician-rated depression assessments in a blinded, independent manner to minimize bias. Maintains separation from other study assessments and treatment decisions for the same participant.

Physiologic monitoring, thermoregulation, hydration, and overdose response

Safely supervises self-administration of esketamine nasal spray according to dose, timing, and visit-order requirements. Ensures all procedural constraints are followed before, during, and after dosing.

Quetiapine XR augmentation management

Initiates, uptitrates, and monitors quetiapine XR augmentation in the comparator arm according to age-specific schedules and tolerability. Recognizes the therapeutic minimum and discontinuation triggers.

PE protocol delivery

Deliver manualized Prolonged Exposure therapy according to the study protocol and standard PE structure. This includes sequencing psychoeducation, in vivo exposure, imaginal exposure, homework review, and relapse prevention across sessions.

Trauma-focused exposure facilitation

Facilitate trauma exposure in a structured, supportive, and protocol-consistent manner. The therapist must be able to initiate, pace, and process exposure work while maintaining adherence to PE methods.

General psychedelic-assisted practice skills

Monitor vital signs, mental status, and adverse effects throughout infusion and recovery. The therapist must recognize when symptoms require escalation and ensure discharge readiness criteria are met.

Physiologic monitoring during ketamine administration

Facilitator must monitor participants for physiologic and psychological safety during and after ketamine administration. The protocol requires close observation and vital-sign monitoring.

MORE delivery

Facilitator can deliver Mindfulness-Oriented Recovery Enhancement (MORE) in an 8-week group format for patients with OUD. The intervention combines mindfulness training, cognitive reappraisal, and savoring techniques.

General psychedelic-assisted practice skills

Facilitator can offer supportive psychotherapeutic interventions during adverse psychological reactions. This includes responding to anxiety, dysphoria, paranoia, or agitation during treatment.

Study record and trial registration literacy

Understands how to interpret study registry information and related administrative text accurately. This supports correctly identifying the intervention, study purpose, and registration context.

Study record and trial registration literacy

Has basic familiarity with clinical trial registration processes and terminology. This helps the facilitator understand where protocol-related competency information would typically be located in trial documentation.

Source verification and documentation awareness

Maintains accuracy and transparency when using registry sources for competency extraction. The facilitator should avoid overclaiming details that are not present in the available record text.

Study record management literacy

Ability to understand and use ClinicalTrials.gov study record guidance when working with study information. This includes awareness of glossary terms and data element definitions used for registration and results reporting.

Motivational enhancement therapy delivery

Therapists are expected to deliver manualised motivational enhancement therapy across preparatory and integration sessions to help participants reduce or stop methamphetamine use. This includes using structured phase-based techniques to build motivation, commitment, and change planning.

Preparation for ketamine sessions

Therapists must prepare participants psychologically and practically for ketamine dosing through rapport-building, psychoeducation, expectation-setting, and intention development. Preparation is emphasized because of trauma burden, psychiatric comorbidity, and instability in the target population.

Monitoring and responding to acute psychological distress

During ketamine sessions, therapists are expected to monitor for challenging psychological experiences and provide immediate supportive interventions. Their role includes de-escalation, reassurance, and use of pre-consented touch within protocol boundaries.

Ketamine-assisted psychotherapy integration

Ability to deliver ketamine in combination with psychotherapy rather than as a stand-alone medication intervention. The clinician/facilitator should tailor treatment to use ketamine's experiential and psychological effects therapeutically.

Psychotherapeutic framing of psychedelic effects

Ability to frame ketamine's psychedelic effects as therapeutically useful rather than undesirable side effects. This requires a clinician stance that normalizes and utilizes the altered experience in treatment.

Safe office-based administration

Ability to provide ketamine in a supervised clinical setting with attention to safe administration. The article emphasizes office-based treatment as a viable model.

No extractable therapist/facilitator competencies in provided source text

The provided source text is a generic ClinicalTrials.gov interface/header snippet and does not contain any study-specific intervention, therapist, facilitator, safety, or ethical competency information.

No extractable therapist or facilitator competencies in provided source text

The provided source text is only a ClinicalTrials.gov interface/header snippet and does not contain study intervention procedures, therapist qualifications, facilitator responsibilities, safety monitoring procedures, or ethical guidance specific to clinical practice.